Medicine & Life Sciences
emicizumab
100%
Acquired Factor 8 deficiency
87%
Blood Platelets
81%
Pure Red-Cell Aplasia
78%
Leukemia, Myelomonocytic, Chronic
76%
Biomarkers
75%
Thrombotic Thrombocytopenic Purpura
70%
Lenalidomide
69%
von Willebrand Diseases
69%
Coronavirus
65%
Paraproteinemias
65%
Bortezomib
64%
Idiopathic Thrombocytopenic Purpura
62%
Germ Cell and Embryonal Neoplasms
61%
Platelet Aggregation Inhibitors
59%
Machine Learning
59%
Sickle Cell Anemia
57%
Anticoagulants
54%
Hepatitis C
53%
von Willebrand Factor
46%
Infections
42%
SARS Virus
41%
Intensive Care Units
39%
Erythrocyte Transfusion
38%
Systematic Reviews
38%
Artificial Respiration
37%
Hemorrhage
36%
Mortality
33%
Hemoglobins
33%
Pediatrics
33%
Thrombopoiesis
32%
Plasma Exchange
31%
Fibrinolytic Agents
31%
Drug Therapy
30%
Factor VIII
29%
Rituximab
28%
Lymphoproliferative Disorders
27%
caplacizumab
26%
Adrenal Cortex Hormones
21%
Therapeutics
20%
prothrombin complex concentrates
18%
recombinant FVIIa
18%
Thrombotic Microangiopathies
17%
Resource Allocation
17%
Cisplatin
17%
Large Granular Lymphocytic Leukemia
16%
Proteasome Inhibitors
15%
Ventilation
15%
Critical Care
15%
Vitamin K
15%